Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phosphate-buffered saline + Incomplete Freund's adjuvant
- Development stage
- Preclinical
- Lead developer
- University of Southern California
- Administration
- Subcutaneous, Intramuscular
01
Overview
phosphate-buffered saline + Incomplete Freund's adjuvant is an experimental control formulation used in immunological and oncological research, specifically within preclinical vaccine studies. It consists of an aqueous phosphate-buffered saline (PBS) phase emulsified with Incomplete Freund's adjuvant (IFA), which is a mixture of paraffin oil and an emulsifying agent (typically mannide monooleate). Unlike Complete Freund's Adjuvant (CFA), IFA does not contain heat-killed mycobacteria, making it less inflammatory while still providing a 'depot' effect. This effect allows for the slow release of substances from the injection site, enhancing the recruitment and activation of antigen-presenting cells. In the context of small cell lung cancer (SCLC) research, this combination is utilized as a negative control to establish baseline survival and immune response metrics against which experimental neo-antigen vaccines, such as those targeting isoaspartylated ELAVL4, are measured.
- Other names
- PBS + IFAPBS in IFAphosphate-buffered saline in Incomplete Freund's adjuvant
Beyond the preview
Go deeper on phosphate-buffered saline + Incomplete Freund's adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phosphate-buffered saline + Incomplete Freund's adjuvant.